Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Dermatologic 1

Conditions

Skin Neoplasms 1Melanoma 1

Interventions

pembrolizumab 259Cyclophosphamide 244Specimen Handling 197fludarabine 175Magnetic Resonance Spectroscopy 173Biopsy 147Nivolumab 122Carboplatin 99Radiotherapy 92Paclitaxel 88venetoclax 82Cisplatin 82fludarabine phosphate 79Gemcitabine 79Injections 69Ipilimumab 64Dexamethasone 62atezolizumab 59Cetuximab 58Bevacizumab 58Azacitidine 57Radiation 56Fluorouracil 56durvalumab 54Radiosurgery 53Temozolomide 48Rituximab 44Oxaliplatin 44Docetaxel 44Irinotecan 43

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Hsp90 inhibitor KU757 × 1 year × Clear all
NCT02721459 2026-03-02

XL888 + Vemurafenib + Cobimetinib for Unresectable BRAF Mutated Stage III/IV Melanoma

H. Lee Moffitt Cancer Center and Research Institute

Phase 1 Active not recruiting
26 enrolled
Dermatologic

Melanoma, Skin Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡